- Published on
Toxicology of Sucralfate
1. Overview
Description
Sucralfate is a gastrointestinal protective medication composed of sucrose and aluminum. It is commonly prescribed for various acid-related gastrointestinal disorders, particularly peptic ulcer disease. Because the drug undergoes minimal systemic absorption, poisoning and serious toxic effects are uncommon. However, prolonged administration may increase the risk of aluminum accumulation in patients with impaired kidney function.
Forms and Clinical Uses
Sucralfate, marketed under the brand name Carafate, is primarily indicated for the treatment of active duodenal ulcers and the prevention of ulcer recurrence following healing. It is also used in the management of other gastrointestinal conditions, including gastroesophageal reflux disease (GERD). The usual adult dosage for ulcer treatment is 1 g orally four times daily. An established pediatric dosage has not been defined in the provided reference.
Toxic Dose
A specific toxic dose of sucralfate has not been established. The medication generally has low toxicity because very little is absorbed from the gastrointestinal tract. Nevertheless, patients with severe renal impairment, particularly those receiving dialysis, may experience aluminum accumulation during prolonged exposure.
2. Pathophysiology
Sucralfate is a minimally absorbed sucrose-aluminum compound that adheres to the gastrointestinal mucosal surface. It forms a protective barrier over damaged tissues, limiting direct exposure to gastric acid and other irritating substances. This local protective action promotes healing of ulcerated gastrointestinal mucosa. Although systemic absorption is limited, the aluminum component may accumulate in individuals with reduced renal clearance, potentially resulting in systemic aluminum toxicity.
3. Epidemiology
Sucralfate poisoning is rarely reported because of its low systemic bioavailability and generally favorable safety profile. Most exposures are associated with mild or no clinical manifestations. Significant toxicity is more likely to occur in patients with advanced kidney disease, especially when the medication is administered for extended periods or alongside other aluminum-containing preparations.
4. Causes of Poisoning
Sucralfate exposure may result from accidental ingestion, inappropriate administration, excessive dosing, or intentional overdose. In infants younger than one year, unexplained ingestion should prompt consideration of possible neglect or abuse when supported by the clinical circumstances. In children older than six years and adolescents, intentional ingestion or self-harm should be considered when evaluating the circumstances of exposure.
5. Drug and Disease Interactions
Patients with advanced renal impairment who are undergoing dialysis have an increased risk of developing aluminum toxicity when treated with sucralfate. Impaired renal elimination may allow aluminum to accumulate in the body, particularly during prolonged treatment or when other aluminum-containing medications are used simultaneously. Such accumulation can contribute to neurological complications and metabolic bone disorders.
6. Pregnancy and Lactation
Sucralfate was historically classified as Pregnancy Category B by the United States Food and Drug Administration (FDA). Under this former classification, animal studies either demonstrated no evidence of fetal harm in the absence of adequate controlled human studies, or animal studies identified adverse effects that were not confirmed in well-controlled studies involving pregnant women. This classification has since been replaced by a more detailed pregnancy risk-labeling system. The provided reference does not specify safety information regarding sucralfate use during breastfeeding.
7. Clinical Manifestations and Symptoms
Dermatological Manifestations
Skin-related adverse effects associated with sucralfate exposure may include cutaneous rashes and urticaria. These manifestations are generally associated with hypersensitivity reactions and are not typical features of severe systemic poisoning.
Gastrointestinal Manifestations
Constipation is the most frequently reported gastrointestinal adverse effect of sucralfate. Other possible symptoms include diarrhea, dyspepsia, and abdominal discomfort. In uncommon cases, sucralfate may accumulate within the gastrointestinal tract and form concretions known as sucralfate bezoars or sucraliths. These masses can produce mechanical gastrointestinal obstruction.
Fluid and Electrolyte Disturbances
Patients receiving dialysis are particularly vulnerable to systemic aluminum accumulation because impaired renal function limits aluminum elimination. Although sucralfate does not typically produce significant fluid or electrolyte disturbances, aluminum toxicity remains an important complication in individuals with end-stage renal disease.
Musculoskeletal Manifestations
Chronic aluminum accumulation in dialysis patients may interfere with normal bone mineralization and contribute to aluminum-related osteodystrophy. Affected individuals may develop persistent bone pain, skeletal weakness, and microscopic bone fractures. These complications are primarily associated with prolonged aluminum exposure.
Neurological Manifestations
Severe aluminum toxicity may affect the central nervous system, particularly in patients undergoing dialysis. Neurological manifestations can include dysarthria, acute encephalopathy, involuntary myoclonic movements, and seizures. Long-standing aluminum accumulation may also contribute to progressive cognitive impairment and dementia-like symptoms.
8. Diagnosis
Differential Diagnosis
Aluminum toxicity should be distinguished from other conditions that produce similar neurological abnormalities. Important differential diagnoses include lithium poisoning, alcohol intoxication, and toxicity caused by anticonvulsant medications such as phenytoin, carbamazepine, and phenobarbital. Careful assessment of medication history, renal function, clinical manifestations, and laboratory findings is essential for identifying the underlying cause.
Essential Laboratory Investigations
Routine laboratory testing is generally unnecessary for asymptomatic patients following isolated sucralfate ingestion because clinically significant toxicity is uncommon. Additional investigations should be considered when patients develop persistent symptoms, have underlying renal disease, or may have ingested other potentially toxic substances.
Serum Aluminum Concentration
Measurement of serum aluminum concentrations is recommended for dialysis patients who exhibit clinical features suggestive of aluminum toxicity. Aluminum concentrations may be assessed in blood, water, and dialysis fluid, commonly using atomic absorption techniques. According to the provided reference, normal serum aluminum concentrations are generally below 15 μg/L. Elevated results should be interpreted together with the patient’s clinical condition and exposure history.
Imaging and Additional Investigations
A barium swallow examination may assist in identifying gastrointestinal bezoars caused by sucralfate accumulation. In suspected intentional overdose or mixed-drug ingestion, an electrocardiogram (ECG) and serum acetaminophen and salicylate concentrations may be appropriate to detect potentially serious co-ingestants.
9. Treatment and Management
General Supportive Management
Treatment of sucralfate exposure is primarily supportive because severe toxicity is unusual and no specific intervention is typically required for uncomplicated ingestion. Initial assessment should prioritize airway protection, breathing, circulation, and neurological status. Clinicians should establish the estimated quantity ingested, the time of exposure, and the presence of additional medications or substances.
Consultation With a Poison Control Center
Consultation with a poison control center is recommended when patients develop severe or persistent symptoms, when potentially harmful co-ingestants are suspected, or when underlying medical conditions and drug interactions complicate treatment. Specialist guidance may also be necessary for patients with renal impairment who show evidence of aluminum toxicity.
Referral to a Healthcare Facility
Hospital evaluation is indicated when the ingestion may have been intentional, including suspected self-harm or assault, or when clinically significant toxic manifestations develop. Patients with complicated co-ingestions, important drug interactions, or serious underlying illnesses should also receive medical assessment.
Hospital Admission Considerations
Dialysis patients presenting with suspected severe aluminum toxicity may require hospital admission and intensive monitoring. Particular attention should be given to patients with neurological abnormalities, seizures, encephalopathy, or other evidence of systemic complications.
10. Decontamination
Out-of-Hospital Management
Inducing vomiting is not recommended following sucralfate ingestion because the medication has a low potential for acute systemic toxicity. Management should instead focus on clinical assessment and observation when appropriate.
In-Hospital Management
Gastric lavage and activated charcoal are generally unnecessary in cases of isolated sucralfate overdose. The medication’s limited systemic absorption and relatively benign toxicity profile make routine gastrointestinal decontamination inappropriate in most cases.
11. Antidotes and Specific Treatment
Deferoxamine Chelation Therapy
Patients undergoing dialysis who develop clinically significant aluminum toxicity may require treatment with deferoxamine, an aluminum-chelating agent. Deferoxamine binds aluminum and facilitates its removal from the body. Chelation may be considered in cases involving aluminum-related encephalopathy, bone demineralization, or other severe manifestations. Such treatment should be conducted under specialist supervision because careful monitoring is necessary.
Adjunctive Treatment
In patients at risk of aluminum accumulation, calcium carbonate may be considered as an alternative to aluminum- or magnesium-containing phosphate binders when clinically appropriate. Avoiding unnecessary exposure to aluminum-containing medications is an important preventive measure, particularly among patients with end-stage renal disease.
12. Follow-Up and Patient Monitoring
Monitoring of Aluminum Concentrations
Patients with end-stage renal disease who are receiving dialysis and taking sucralfate may require monitoring for aluminum accumulation. Serum aluminum concentrations should be assessed when toxicity is suspected, and follow-up investigations should be guided by clinical findings, treatment history, and specialist recommendations.
Expected Clinical Course and Prognosis
The prognosis following isolated sucralfate ingestion is generally favorable in patients with normal renal function. Most cases remain asymptomatic or produce only mild gastrointestinal symptoms. Serious complications are uncommon but may occur in patients with impaired renal clearance, particularly after prolonged exposure resulting in aluminum accumulation.
13. Discharge Criteria and Instructions
Patients who remain asymptomatic following evaluation for isolated sucralfate ingestion may generally be discharged when no additional clinical concerns are identified. Routine gastrointestinal decontamination is usually unnecessary. When an intentional overdose is suspected, appropriate psychiatric or psychosocial assessment should be completed before discharge. Patients should receive guidance regarding medication use and symptoms that warrant further medical attention.
14. Diagnostic and Treatment Pitfalls
Diagnostic Pitfalls
An important diagnostic error is failing to recognize aluminum toxicity as a possible cause of neurological deterioration or dementia-like symptoms in patients with advanced renal disease. Because the neurological manifestations may resemble other toxicological or metabolic disorders, a detailed medication history and consideration of chronic aluminum exposure are essential.
Treatment Pitfalls
Prolonged use of sucralfate in patients with end-stage renal disease may increase the risk of aluminum toxicity. This risk becomes particularly important when patients are simultaneously receiving other aluminum-containing medications. Failure to identify cumulative aluminum exposure may delay recognition and management of neurological and skeletal complications.
15. International Classification of Diseases (ICD)
The historical ICD-9-CM code 976.3 refers to poisoning by agents primarily affecting the skin and mucous membranes, including certain ophthalmological, otorhinolaryngological, and dental preparations, as well as emollients, demulcents, and protectants. This classification was included in the original toxicology reference.
16. Conclusion
Sucralfate is a gastrointestinal mucosal protective agent with a relatively low risk of acute poisoning due to its minimal systemic absorption. Most isolated ingestions produce mild or no adverse effects, with constipation being the most frequently observed gastrointestinal complaint. However, prolonged exposure in patients with significant renal impairment may result in aluminum accumulation, potentially causing neurological dysfunction, encephalopathy, and metabolic bone disease. Management generally involves supportive care, appropriate clinical assessment, and monitoring for complications. Patients with severe aluminum toxicity may require specialist-directed chelation therapy and measures to reduce further aluminum exposure.